GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young ...

Bharat Biotech and GSK plc have partnered to develop a vaccine for Shigellosis, a severe bacterial diarrhea. The altSonflex1-2-3 vaccine candidate, developed by GSK, will be further developed by ...

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and ...

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development ...

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine ...

Bharat Biotech on Thursday said it has partnered with GSK plc for the development of a vaccine for Shigellosis, a severe form ...

Bharat Biotech and GSK collaborate to develop a vaccine for Shigellosis, a severe form of bacterial diarrhea. The innovative ...

India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...